- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01583218
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) (APEX)
August 3, 2023 updated by: Portola Pharmaceuticals
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin.
The safety of betrixaban will also be studied.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
7513
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, 1280
-
Ciudad Autónoma de Buenos Aires, Argentina, C1181ACH
-
Cordoba, Argentina, 5000
-
Coronel Suarez, Buenos Aires, Argentina, B7540DOL
-
Corrientes, Argentina, W3400AMZ
-
Córdoba, Argentina, 5000
-
El Talar, Argentina, 1618
-
Rosario, Santa Fe, Argentina, S2000DSV
-
San Miguel de Tucumán, Argentina, T4000JCU
-
-
-
-
-
Milton, Australia, Qld 4064
-
Parkville, Australia, Vic 3050
-
Randwick, Australia
-
Richmond, Australia, Vic 3121
-
-
Queensland
-
Redcliffe, Queensland, Australia, 4020
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
-
-
-
-
-
Feldkirch, Austria, 6800
-
Gratwein, Austria, 8112
-
Graz, Austria, 8036
-
Hartberg, Austria, 8230
-
Linz, Austria, 4020
-
Wien, Austria, 1100
-
Wien, Austria, 1160
-
Zams, Austria, 6511
-
-
-
-
-
Bruxelles, Belgium, 1070
-
Huy, Belgium, 4500
-
Leper, Belgium, 8900
-
Leuven, Belgium, 3000
-
Yvoir, Belgium, 5530
-
-
-
-
-
Belo Horizonte - MG, Brazil, 30150-221
-
Botucatu, Brazil, 18618-970
-
Brasilia, Brazil, 70710
-
Brasilia/DF, Brazil, 70710-905
-
Campinas, Brazil, 13083-970
-
Campinas, Sao Paulo, Brazil, 13059-740
-
Curitiba - PR, Brazil, 80030-001
-
Porto Alegre, Brazil, 90620-001
-
Porto Alegre, Brazil, 90880-480
-
Porto Alegre/RS, Brazil, 90620-001
-
Salvador, Brazil, 41810-011
-
Salvador/BA, Brazil, 40140-110
-
Salvador/BA, Brazil, 41810-011
-
Sao Paulo, Brazil, 04012-909
-
SãO Paulo, Brazil, 01323-903
-
São José Do Rio Preto- SP, Brazil, 15090-000
-
São Paulo, Brazil, 01308-050
-
-
-
-
-
Gabrovo, Bulgaria, 5300
-
Pleven, Bulgaria, 5800
-
Plovdiv, Bulgaria, 4002
-
Sandanski, Bulgaria, 2800
-
Sliven, Bulgaria, 8800
-
Sofia, Bulgaria
-
Sofia, Bulgaria, 1784
-
Sofia, Bulgaria, 1233
-
Sofia, Bulgaria, 1606
-
Sofia, Bulgaria, 1202
-
Sofia, Bulgaria, 1407
-
Yambol, Bulgaria, 8600
-
-
-
-
-
Ontario, Canada, N8X 5A6
-
Quebec, Canada, G1V 4G5
-
-
Alberta
-
Edmonton, Alberta, Canada, T6K4B3
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
-
Hamilton, Ontario, Canada, L8N 4A6
-
Kitchener, Ontario, Canada, N2M1B2
-
Ottawa, Ontario, Canada, K1H 8L6
-
Thunder Bay, Ontario, Canada, P7B 6R4
-
-
Quebec
-
Montreal, Quebec, Canada, H1T2M4
-
-
-
-
-
La Serena, Chile, 170000
-
Osorno, Chile
-
Santiago, Chile
-
Santiago, Chile, 7650568
-
Temuco, Chile, 4781173
-
Viña del Mar, Chile, 2570017
-
-
-
-
-
Krapinske Toplice, Croatia, 49217
-
Pula, Croatia, 52100
-
Rijeka, Croatia, 51000
-
Varazdin, Croatia, 42000
-
Zadar, Croatia, 23000
-
Zagreb, Croatia, 10000
-
Zagreb, Croatia, 1000
-
-
-
-
-
Caslav, Czechia, 286 01
-
Chrudim, Czechia, 537 27
-
Hradec Kralove, Czechia, 500 05
-
Kladno, Czechia, 272 01
-
Kromeriz, Czechia, 76701
-
Kyjov, Czechia, 697 33
-
Liberec, Czechia, 460 63
-
Litomysl, Czechia, 570 14
-
Olomouc, Czechia, 771 11
-
Ostrava, Czechia, 703 84
-
Plzen - Bory, Czechia, 305 99
-
Praha, Czechia, 128 08
-
Praha 1, Czechia, 110 00
-
Praha 1, Czechia, 118 00
-
Praha 10, Czechia, 100 34
-
Praha 5, Czechia, 150 06
-
Slany, Czechia, 274 01
-
Strakonice, Czechia, 386 29
-
Teplice, Czechia, 415 29
-
Usti nad Labem, Czechia, 401 13
-
Zlin, Czechia, 762 75
-
Znojmo, Czechia, 669 02
-
-
-
-
-
Aarhus N, Denmark, DK-8200
-
Frederiksberg, Denmark, DK-2000
-
Glostrup, Denmark, DK-2600
-
Haderslev, Denmark, DK-6100
-
Hellerup, Denmark, DK-2900
-
Hillerod, Denmark, DK-3400
-
Hvidovre, Denmark, DK-2650
-
Kobenhavn NV, Denmark, DK-2400
-
Silkeborg, Denmark, DK-8600
-
Slagelse, Denmark, DK-4200
-
-
-
-
-
Tallinn, Estonia, EE-13419
-
Tallinn, Estonia, EE-10138
-
Tartu, Estonia, EE-51014
-
-
-
-
-
Helsinki, Finland, FI-00290
-
Jyväskylä, Finland, FI-40620
-
Kouvola, Finland, FI-45750
-
Mikkeli, Finland, FI-50100
-
Pori, Finland, FI-28500
-
Tampere, Finland
-
Turku, Finland, FI-20520
-
-
-
-
-
Angers, France, 49100
-
Arras, France, 62022
-
Avignon, France, 84918
-
Bois-Guillaume, France, 76230
-
Bordeaux, France, 33075
-
Brest, France, 29609
-
Brest, France, 29200
-
Cambrai, France, 59400
-
Castelnau-le-Lez, France, 34170
-
Clermont-Ferrand, France, 63003
-
Colombes, France, 92700
-
Dijon, France, 21079
-
La Tronche, France, 38043
-
Le Mans, France, 72037
-
Lille, France, 59020
-
Limoges, France, 87 042
-
Montpellier, France, 34295
-
Nantes, France, 44093
-
Nimes, France, 30029 cedex 9
-
Paris, France, 75908
-
Paris, France, 75010
-
Paris, France, 75004
-
Pierre Benite, France, 69495
-
Quimper, France, 29107
-
Rennes, France, 35203
-
Saint-Priest En Jarrez, France, 42055
-
Tourcoing, France, 59200
-
Valenciennes, France, 59300
-
Vernon, France, 27207
-
-
-
-
-
Tbilisi, Georgia, 0144
-
Tbilisi, Georgia, 0159
-
Tbilisi, Georgia, 0183
-
-
-
-
-
Altenburg, Germany, 04600
-
Bad Friedrichshall, Germany, 74173
-
Berlin, Germany, 10787
-
Bonn, Germany, 53115
-
Dresden, Germany, 01307
-
Dresden, Germany, 01067
-
Essen, Germany, 45147
-
Hamburg, Germany, 22559
-
Heidelberg, Germany, 69120
-
Karlbad, Germany, 76307
-
Ludwigshafen, Germany, 67063
-
Magdeburg, Germany, 39120
-
Mainz, Germany, 55131
-
Minden, Germany, 32429
-
Möchengladbach, Germany, 41063
-
Neuss, Germany, 41464
-
Oberhausen, Germany, 46045
-
Paderborn, Germany, 33098
-
Rüsselsheim, Germany, 65428
-
Troisdorf, Germany
-
Weiden, Germany, 92637
-
Wesel, Germany, 46483
-
Wiesbaden, Germany, 65199
-
Witten, Germany, 58455
-
-
-
-
-
Baja, Hungary, 6500
-
Balassagyarmat, Hungary, 2660
-
Balatonfüred, Hungary, 8231
-
Berettyóújfalu, Hungary, 4100
-
Budapest, Hungary, 1125
-
Budapest, Hungary, 1122
-
Budapest, Hungary, 1145
-
Budapest, Hungary, 1097
-
Budapest,, Hungary, 1134
-
Cegléd, Hungary, 2700
-
Debrecen, Hungary, 4032
-
Debrecen, Hungary, H-4012
-
Eger, Hungary, 3300
-
Gyula, Hungary, 5700
-
Hódmezövásárhely, Hungary, 6800
-
Kistarcsa, Hungary, 2143
-
Mohács, Hungary, 7700
-
Nagykanizsa, Hungary, 8800
-
Szekszárd, Hungary, 7100
-
Szolnok, Hungary, 5000
-
Veszprém, Hungary, 8200
-
Zalaegerszeg, Hungary, 8900
-
-
-
-
-
Afula, Israel, 18101
-
Ashkelon, Israel, 78278
-
Haifa, Israel, 31048
-
Haifa, Israel, 31096
-
Jerusalem, Israel, 91120
-
Kfar Saba, Israel, 44281
-
Petach Tikva, Israel, 49100
-
Safed, Israel, 13100
-
Tel Aviv, Israel, 64239
-
Zerifin, Israel, 70300
-
-
-
-
-
Bollate, Italy, 20021
-
Frenze, Italy, 50134
-
Genova, Italy, 16128
-
Milano, Italy, 20132
-
Milano, Italy, 20085
-
Napoli, Italy, 80131
-
Parma, Italy, 43100
-
Pavia, Italy, 27100
-
Piacenza, Italy, 29121
-
Reggio Emilia, Italy, 42100
-
Roma, Italy, 00168
-
Varese, Italy, 21100
-
Venezia, Italy, 30122
-
Vittorio Veneto TV, Italy, 31029
-
-
Treviso
-
Castelfranco Veneto, Treviso, Italy, 31033
-
-
-
-
-
Daugavpils, Latvia, LV-5417
-
Liepaja, Latvia, LV-3414
-
Riga, Latvia, LV-1002
-
Riga, Latvia, LV-1038
-
Valmiera, Latvia, LV-4201
-
-
-
-
-
Alytus, Lithuania, LT-62114
-
Kaunas, Lithuania, LT-47144
-
Kaunas, Lithuania, LT-44320
-
Kaunas, Lithuania, LT-45130
-
Klaipeda, Lithuania, LT-92231
-
Klaipeda, Lithuania, LT-92288
-
Siauliai, Lithuania, LT-76231
-
Utena, Lithuania, 28151
-
Vilnius, Lithuania, LT-04130
-
Vilnius, Lithuania, LT-10207
-
Vilnius, Lithuania, LT-08411
-
-
-
-
MS
-
Picayune, MS, Montserrat, 39466
-
-
-
-
-
Arequipa, Peru, 05154
-
Callao, Peru, CALLAO 2
-
Lima, Peru, 01
-
Lima, Peru, 18
-
Lima, Peru, Lima 11
-
Lima, Peru, LIMA 13
-
-
-
-
-
Bialystok, Poland, 15-276
-
Bydgoszcz, Poland, 85-681
-
Bydgoszcz, Poland, 85-168
-
Czeladz, Poland, 41-250
-
Gdansk, Poland, 80-803
-
Krakow, Poland, 31-121
-
Krakow, Poland, 31-913
-
Skierniewice, Poland, 96-100
-
Tarnobrzeg, Poland, 39-400
-
Warszawa, Poland, 01-138
-
Warszawa, Poland, 02-097
-
Wloclawek, Poland, 87-800
-
-
-
-
-
Baia, Romania, 430031
-
Bucharest, Romania, 022328
-
Bucharest, Romania, 021659
-
Bucharest, Romania, 020475
-
Bucharest, Romania, 041915
-
Cluj Napoca, Romania, 400006
-
Cluj-Napoca, Romania, 40001
-
Craiova, Romania, 200642
-
Iasi, Romania, 700620
-
Oradea, Romania, 410169
-
Pitesti, Romania, 110884
-
Targu Mures, Romania, 540136
-
Timisoara, Romania, 300736
-
-
-
-
-
Arkhangelsk, Russian Federation, 163045
-
Barnaul, Russian Federation, 656045
-
Barnaul, Russian Federation, 656024
-
Belgorod, Russian Federation, 308007
-
Chelyabinsk, Russian Federation, 454048
-
Chelyabinsk, Russian Federation, 454091
-
Ekaterinburg, Russian Federation, 620039
-
Ekaterinburg, Russian Federation, 620219
-
Irkutsk, Russian Federation, 664049
-
Kaluga, Russian Federation, 428007
-
Kazan, Russian Federation, 420012
-
Kazan, Russian Federation, 420043
-
Kemerovo, Russian Federation, 650002
-
Kirov, Russian Federation, 610014
-
Krasnodar, Russian Federation, 350086
-
Lubertsy, Russian Federation, 140006
-
Moscow, Russian Federation, 119992
-
Moscow, Russian Federation, 111539
-
Moscow, Russian Federation, 121552
-
Moscow, Russian Federation, 119881
-
Moscow, Russian Federation, 117292
-
Moscow, Russian Federation, 127473
-
Murmansk, Russian Federation, 183047
-
Novosibirsk, Russian Federation, 630051
-
Novosibirsk, Russian Federation, 630054
-
Novosibirsk, Russian Federation, 630007
-
Rostov-on-Don, Russian Federation, 344022
-
Samara, Russian Federation, 443070
-
Saratov, Russian Federation, 410028
-
Saratov, Russian Federation, 410054
-
Saratov, Russian Federation, 410053
-
Smolensk, Russian Federation, 214018
-
St. Petersburg, Russian Federation, 197022
-
St. Petersburg, Russian Federation, 192242
-
St. Petersburg, Russian Federation, 196247
-
St. Petersburg, Russian Federation, 199106
-
St. Petersburg, Russian Federation, 195067
-
St. Petersburg, Russian Federation, 198205
-
St.Petersburg, Russian Federation, 191025
-
Tomsk, Russian Federation, 643012
-
Yaroslavl, Russian Federation, 150030
-
Yaroslavl, Russian Federation, 150003
-
-
-
-
-
Belgrade, Serbia, 11000
-
Kragujevac, Serbia, 34000
-
Nis, Serbia, 18000
-
Niska Banja, Serbia, 18205
-
Pancevo, Serbia, 26000
-
Sremska Kamenica, Serbia, 21204
-
-
-
-
-
Singapore, Singapore, 169608
-
Singapore, Singapore, 119074
-
Singapore, Singapore, 169609
-
-
-
-
-
Bratislava, Slovakia, 83305
-
Nitra, Slovakia, 94901
-
Nitra, Slovakia, 949 01
-
-
-
-
-
Pretoria, South Africa, Gauteng 0084
-
Worcester, South Africa, 6850
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2193
-
Johannesburg, Gauteng, South Africa, 2021
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7530
-
-
-
-
-
Barcelona, Spain, 08041
-
Barcelona, Spain, 08023
-
Cartagena, Spain, 30202
-
Girona, Spain, 17007
-
Olot, Spain, 17800
-
Pontevedra, Spain, 36001
-
Salamanca, Spain, 37007
-
Terrassa, Spain, 08221
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08003
-
Barcelona, Cataluña, Spain, 08036
-
L'Hospitalet de Llobregat, Cataluña, Spain, 08907
-
Sabadell, Cataluña, Spain, 08208
-
Sant Boi de Llobregat, Cataluña, Spain, '08830
-
Tarragona, Cataluña, Spain, 43007
-
-
Communidad De
-
Madrid, Communidad De, Spain, 28007
-
-
Comunidad Valenciana
-
Orihuela, Comunidad Valenciana, Spain, 03314
-
-
Galicia
-
Vigo, Galicia, Spain, 36204
-
-
Madrid, Communidad De
-
Madrid, Madrid, Communidad De, Spain, 28034
-
Majadahonda, Madrid, Communidad De, Spain, 28222
-
San Sebastián de los Reyes, Madrid, Communidad De, Spain, 28702
-
-
-
-
-
Donetsk, Ukraine, 83114
-
Donetsk, Ukraine, 83045
-
Ivano-Frankivsk, Ukraine
-
Ivano-Frankivsk, Ukraine, 76008
-
Kharkiv, Ukraine, 61039
-
Kharkiv, Ukraine, 61176
-
Kharkiv, Ukraine, 61018
-
Kharkiv,, Ukraine, 61058
-
Kherson, Ukraine, 73039
-
Kirovograd, Ukraine, 25006
-
Kyiv, Ukraine, 02660
-
Kyiv, Ukraine, 02091
-
Kyiv, Ukraine, 01023
-
Kyiv, Ukraine, 03680
-
Kyiv, Ukraine, 04060
-
Lugansk, Ukraine, 91011
-
Lutsk, Ukraine, 43024
-
Lviv, Ukraine, 79010
-
Odesa, Ukraine, 65025
-
Odesa, Ukraine, 65014
-
Odesa, Ukraine, 65009
-
Rivne, Ukraine, 33001
-
Simferopol, Ukraine, 95026
-
Uzhgorod, Ukraine, 88000
-
Vinnytsya, Ukraine, 21005
-
Yevpatoriya, Ukraine, 97400
-
Zaporizhzhya, Ukraine, 69000
-
Zaporizhzhya, Ukraine, 69065
-
-
-
-
-
London, United Kingdom, SE5 9RS
-
London, United Kingdom, EC1M 6BQ
-
London, United Kingdom, WC1E 6HX
-
Manchester, United Kingdom, M23 9LT
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
-
Romford, United Kingdom, RM7 0AG
-
Southall, United Kingdom, UB1 3HW
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
-
-
California
-
Bakersfield, California, United States, 93308
-
Fresno, California, United States, 93701
-
La Mesa, California, United States, 91942
-
Long Beach, California, United States, 90822
-
Los Angeles, California, United States, 90073
-
Modesto, California, United States, 95350
-
San Diego, California, United States, 92120
-
Stanford, California, United States, 94305
-
Torrance, California, United States, 90509
-
-
Colorado
-
Englewood, Colorado, United States, 80113
-
-
Florida
-
Bay Pines, Florida, United States, 33744
-
Clearwater, Florida, United States, 33756
-
Jacksonville, Florida, United States, 32216
-
Miami, Florida, United States, 33143
-
Pensacola, Florida, United States, 32504
-
Sarasota, Florida, United States, 34232
-
Vero Beach, Florida, United States, 32960
-
-
Georgia
-
Columbus, Georgia, United States, 31904
-
Decatur, Georgia, United States, 30030
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
Oak Park, Illinois, United States, 60302
-
-
Indiana
-
Carmel, Indiana, United States, 46032
-
-
Iowa
-
Davenport, Iowa, United States, 52803
-
Windsor Heights, Iowa, United States, 50324
-
-
Kansas
-
Topeka, Kansas, United States, 66604
-
-
Kentucky
-
Hazard, Kentucky, United States, 41701
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
-
Baltimore, Maryland, United States, 21287
-
-
Michigan
-
Detroit, Michigan, United States, 48202
-
Grand Blanc, Michigan, United States, 48439
-
Royal Oak, Michigan, United States, 48073
-
Troy, Michigan, United States, 48085
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
-
-
Mississippi
-
Picayune, Mississippi, United States, 39466
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
-
Saint Louis, Missouri, United States, 63110
-
-
Montana
-
Butte, Montana, United States, 59701
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
-
Reno, Nevada, United States, 89502
-
-
New Jersey
-
Atlantic City, New Jersey, United States, 08401
-
Pomona, New Jersey, United States, 08240
-
Somerville, New Jersey, United States, 08876
-
Summit, New Jersey, United States, 07901
-
-
New York
-
Buffalo, New York, United States, 14209
-
Manhasset, New York, United States, 11030
-
Staten Island, New York, United States, 10305
-
Valhalla, New York, United States, 10595
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
-
Cleveland, Ohio, United States, 44106-5072
-
Columbus, Ohio, United States, 43210
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, United States, 17011
-
Philadelphia, Pennsylvania, United States, 19107
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
-
Orangeburg, South Carolina, United States, 29118
-
-
Texas
-
Austin, Texas, United States, 78705
-
Austin, Texas, United States, 78752
-
Bellaire, Texas, United States, 77401
-
Corsicana, Texas, United States, 75110
-
Dallas, Texas, United States, 75216
-
Fort Worth, Texas, United States, 76104
-
Houston, Texas, United States, 77030
-
Houston, Texas, United States, 77024
-
McAllen, Texas, United States, 78501
-
Mission, Texas, United States, 78572
-
San Antonio, Texas, United States, 78258
-
San Antonio, Texas, United States, 78205
-
Victoria, Texas, United States, 77901
-
-
Vermont
-
Colchester, Vermont, United States, 05401
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
-
Richmond, Virginia, United States, 23249
-
-
Washington
-
Everett, Washington, United States, 98201
-
-
West Virginia
-
Huntington, West Virginia, United States, 25701
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- men and non-pregnant, non-breastfeeding women
- anticipated to be severely immobilized for at least 24 hours after randomization
hospitalized with one of the following
- congestive heart failure
- acute respiratory failure,
- acute infection without septic shock,
- acute rheumatic disorders
- acute ischemic stroke with lower extremity hemiparesis or hemi paralysis
Exclusion Criteria:
- a condition requiring prolonged anticoagulation or anti-platelets
- active bleeding or at high risk of bleeding
- contraindication to anticoagulant therapy
- general conditions in which subjects are not suitable to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Betrixaban
Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
|
Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days. Enoxaparin Placebo: Once daily, 6-14 days |
|
Active Comparator: Enoxaparin
Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
|
Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days. Betrixaban Placebo: once daily, 35 days |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3
Time Frame: mITT Cohort 1: Between randomization and Day 47 (max)
|
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1).
|
mITT Cohort 1: Between randomization and Day 47 (max)
|
|
mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3
Time Frame: mITT Cohort 2: Between randomization and Day 47 (max)
|
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1).
|
mITT Cohort 2: Between randomization and Day 47 (max)
|
|
mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3
Time Frame: mITT: Between randomization and Day 47 (max)
|
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1).
|
mITT: Between randomization and Day 47 (max)
|
|
Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication
Time Frame: Between randomization and Day 49 (max)
|
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication.
|
Between randomization and Day 49 (max)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mITT Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3
Time Frame: mITT Cohort 1: Between randomization and Day 42 (max)
|
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1).
|
mITT Cohort 1: Between randomization and Day 42 (max)
|
|
mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3
Time Frame: mITT Cohort 2: Between randomization and Day 42 (max)
|
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1).
|
mITT Cohort 2: Between randomization and Day 42 (max)
|
|
mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3
Time Frame: mITT: Between randomization and Day 42 (max)
|
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1).
|
mITT: Between randomization and Day 42 (max)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Jamil A, Jamil U, Singh K, Khan F, Chi G. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups. Crit Pathw Cardiol. 2021 Mar 1;20(1):16-24. doi: 10.1097/HPC.0000000000000232.
- Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017 Oct;15(10):1913-1922. doi: 10.1111/jth.13783. Epub 2017 Sep 4.
- Marszalek J, Mehrsefat S, Chi G. The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis. Expert Rev Hematol. 2017 Aug;10(8):679-684. doi: 10.1080/17474086.2017.1343662. Epub 2017 Jun 21.
- Yee MK, Gibson CM, Nafee T, Kerneis M, Daaboul Y, Korjian S, Chi G, AlKhalfan F, Hernandez AF, Hull RD, Cohen AT, Goldhaber SZ. Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. TH Open. 2019 Apr 17;3(2):e103-e108. doi: 10.1055/s-0039-1685496. eCollection 2019 Apr.
- Guy H, Laskier V, Fisher M, Bucior I, Deitelzweig S, Cohen AT. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Expert Rev Pharmacoecon Outcomes Res. 2020 Jun;20(3):259-267. doi: 10.1080/14737167.2019.1629905. Epub 2019 Jun 19.
- Chi G, Gibson CM, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 Apr;45(4):477-487. doi: 10.1007/s00134-019-05565-6. Epub 2019 Feb 18.
- Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec;118(12):2046-2052. doi: 10.1055/s-0038-1675606. Epub 2018 Nov 12.
- Chi G, Gibson CM, Liu Y, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 Jan;94(1):21-28. doi: 10.1002/ajh.25296. Epub 2018 Oct 17.
- Chi G, Goldhaber SZ, Hull RD, Hernandez AF, Kerneis M, Al Khalfan F, Cohen AT, Harrington RA, Gibson CM. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 Dec;117(12):2389-2395. doi: 10.1160/TH17-08-0538. Epub 2017 Dec 6.
- Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. J Thromb Thrombolysis. 2018 Jan;45(1):1-8. doi: 10.1007/s11239-017-1583-0.
- Chi G, Januzzi JL, Korjian S, Daaboul Y, Goldhaber SZ, Hernandez AF, Hull RD, Gold A, Cohen AT, Harrington RA, Gibson CM. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017 Nov;44(4):457-465. doi: 10.1007/s11239-017-1552-7.
- Arbetter DF, Jain P, Yee MK, Michalak N, Hernandez AF, Hull RD, Goldhaber SZ, Harrington RA, Gold A, Cohen AT, Gibson CM. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharm Stat. 2017 Nov;16(6):445-450. doi: 10.1002/pst.1823. Epub 2017 Aug 24.
- Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA; APEX Investigators. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11;6(7):e006015. doi: 10.1161/JAHA.117.006015.
- Gibson CM, Goldhaber SZ, Cohen AT, Nafee T, Hernandez AF, Hull R, Korjian S, Daaboul Y, Chi G, Yee M, Harrington RA. When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. Am Heart J. 2017 Jul;189:1-8. doi: 10.1016/j.ahj.2017.03.018. Epub 2017 Mar 31. No abstract available.
- Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT; APEX Investigators. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 Feb 14;135(7):648-655. doi: 10.1161/CIRCULATIONAHA.116.025427. Epub 2016 Nov 14.
- Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.
- Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J. 2014 Mar;167(3):335-41. doi: 10.1016/j.ahj.2013.11.006. Epub 2013 Dec 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
April 16, 2012
First Submitted That Met QC Criteria
April 19, 2012
First Posted (Estimated)
April 23, 2012
Study Record Updates
Last Update Posted (Actual)
August 7, 2023
Last Update Submitted That Met QC Criteria
August 3, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thromboembolism
- Venous Thromboembolism
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Enoxaparin
- Betrixaban
Other Study ID Numbers
- 11-019
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism (VTE)
-
Infanta Leonor University HospitalFundación para la Investigación e Innovación Biomédica del Hospital Universitario...RecruitingVenous Thromboembolism (VTE) | Occult CancerSpain
-
McMaster UniversityCanadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR)... and other collaboratorsNot yet recruitingVenous Thromboembolism (VTE) | Hip Fracture Surgery | Cardiovascular PreventionCanada, Italy
-
Thomas Jefferson UniversityRecruitingBreastfeeding | Postpartum | Breast Milk Collection | Rivaroxaban | VTE Prophylaxis | VTE (Venous Thromboembolism)United States
-
Regeneron PharmaceuticalsRecruitingVenous Thromboembolism (VTE)United States, Japan, Lithuania, Hungary, Latvia, Poland, Bulgaria, Romania
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
University of VermontRecruitingCancer | VTE (Venous Thromboembolism)United States
-
Beijing Friendship HospitalNot yet recruitingColorectal Surgery | VTE (Venous Thromboembolism)
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE) | Post Partum WomenFrance
Clinical Trials on Betrixaban
-
Portola PharmaceuticalsCompleted
-
Portola PharmaceuticalsCompletedAtrial FibrillationUnited States, Canada
-
Portola PharmaceuticalsCompletedAtrial Fibrillation | Atrial Flutter
-
Portola PharmaceuticalsTerminated
-
Alexion Pharmaceuticals, Inc.Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)TerminatedVTE ProphylaxisUnited States, United Kingdom, Russian Federation, Ukraine
-
Portola PharmaceuticalsCompleted
-
Portola PharmaceuticalsMerck Sharp & Dohme LLCCompleted
-
Portola PharmaceuticalsCompletedHepatic ImpairmentUnited States
-
Portola PharmaceuticalsCompleted
-
Brian O'Neill MDLifetech Scientific (Shenzhen) Co., Ltd.WithdrawnAtrial Fibrillation | Left Atrial Appendage Thrombosis | CVAUnited States